Search clinical trials for: CHS-1701

Total 3947 results

Coherus Biosciences, Inc.

Completed

Study to Assess the Pharmacokinetic and Pharmacodynamic Bioequivalence of CHS-1701 With Neulasta

Healthy

United States
Coherus Biosciences, Inc.

Completed

Comparison of the Pharmacokinetic and Pharmacodynamic Biosimilarity of CHS-1701 (Coherus Pegfilgrastim) With Neulasta® (Pegfilgrastim)

Bioequivalence

United States
Coherus Biosciences, Inc.

Completed

Assessing the Immunogenicity of 2 Subcutaneous Doses of CHS-1701 (Coherus Pegfilgrastim) With 2 Subcutaneous Doses Neulasta®

Immunity, Humoral

United States
TG Therapeutics, Inc.

Active, not recruiting

Study of TG-1801 Alone or in Combination With Ublituximab in Subjects With B-Cell Lymphoma or Chronic Lymphocytic Leukemia

Follicular Lymphoma | Marginal Zone Lymphoma | DLBCL | CLL | MCL | Indolent Lymphoma | Richter's Transformation | SLL | Mediastinal Large B-cell Lymphoma | Aggressive Lymphoma

United States
Canopy Growth Corporation

Completed

Study to Assess the Safety, Tolerability, and Effects of CHI-202 to Support Recovery From Physical Activity

Delayed Onset Muscle Soreness (DOMS)

United States
TG Therapeutics, Inc.

Active, not recruiting

Study of TG-1701, an Irreversible Bruton's Tyrosine Kinase Inhibitor, in Patients With B-Cell Malignancies

Chronic Lymphocytic Leukemia | Non Hodgkin Lymphoma

Australia, Poland
The University of Texas Health Science Center,...
Cancer Prevention Research Institute of Texas

Completed

Using a Lay Health Worker Program to Increase Breast and Cervical Cancer Screening in Low-Income Hispanic Women

Cervical Cancer | Breast Cancer

United States
Apollomics Inc.

Recruiting

APL-101 Study of Subjects With NSCLC With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors (SPARTA)

Gastric Cancer | Pancreatic Cancer | NSCLC | Lung Cancer | Brain Tumor | Glioblastoma Multiforme | Advanced Cancer | Colon Cancer | Solid Tumors | Thyroid Cancer | Renal Cancer | Gastroesophageal Junction Adenocarcinoma | EGFR Gene Mutation | MET Amplification | HGF | MET Alteration | MET Fusion | Exon 14 Skipping

United States, Spain, France, United Kingdom, Taiwan, Australia, Finland, Italy, Singapore, Hungary, Canada, Puerto Rico, Russian Federation
PATH
GlaxoSmithKline; Icahn School of Medicine at Mount Sinai; Duke University; Children... and other collaborators

Completed

Safety and Immunogenicity of a Live-attenuated Universal Flu Vaccine Followed by an Inactivated Universal Flu Vaccine

Influenza | Vaccine

United States
TG Therapeutics, Inc.

Completed

Study of TG-1801 in Subjects With B-Cell Lymphoma

B-Cell Lymphoma

Australia
Brainvectis, a subsidiary of Asklepios BioPharmaceutical...

Active, not recruiting

A Study to Evaluate AB-1001 Striatal Administration in Adults With Early Manifest Huntington's Disease

Huntington Disease

France
TG Therapeutics, Inc.
Memorial Sloan Kettering Cancer Center

Completed

Study of Immunotherapy in Combination With Ublituximab and Umbralisib in Patients With Relapsed-refractory CLL or Richter's Transformation

Chronic Lymphocytic Leukemia | Richter Syndrome

United States
Gilead Sciences

Terminated

Entospletinib in Combination With Idelalisib in Adults With Relapsed or Refractory Hematologic Malignancies

Mantle Cell Lymphoma | Chronic Lymphocytic Leukemia | Diffuse Large B-cell Lymphoma | Indolent Non-Hodgkin's Lymphoma

United States
Jiangsu HengRui Medicine Co., Ltd.

Not yet recruiting

A Trial of SHR-1701 in Combination With and Without Famitinib Malate in Patients With Extensive Stage Small Cell Lung Cancer

Lung Cancer
Jiangsu HengRui Medicine Co., Ltd.

Withdrawn

A Trial of SHR-1701 With or Without Famitinib in Patients With Advanced or Metastatic NSCLC

Non-Small-Cell Lung Cancer
Heuron Inc.

Completed

Evaluation of Clinical Decision Support System for Intracranial Hemorrhage Using Brain CT Images

Intracranial Hemorrhages

Korea, Republic of
GlaxoSmithKline

Completed

A Study to Evaluate the Reactogenicity, Safety and Immunogenicity of GlaxoSmithKline (GSK) Biologicals' Investigational Supra-seasonal Universal Influenza Vaccines - Inactivated (SUIVs) (GSK3816302A) in Healthy Adults Aged 18 to 39 Years

Influenza, Human

United States, Belgium
Apollomics Inc.

Recruiting

A Study Comparing Two Different Capsules, APL-101 and PLB-1001 Capsules, in Healthy Chinese and Caucasian Participants

Bioequivalence

New Zealand
Coherus Biosciences, Inc.
Shire; Daiichi Sankyo Co., Ltd.

Completed

A Long Term Safety Extension Study (CHS-0214-05)

Rheumatoid Arthritis | Plaque Psoriasis

Japan
European Organisation for Research and Treatment...

Withdrawn

CHS 828 in Treating Patients With Solid Tumors

Unspecified Adult Solid Tumor, Protocol Specific

France, Norway, Switzerland, Netherlands, Belgium, Austria, United Kingdom, Denmark, Germany
Wake Forest University Health Sciences

Completed

Aiming to Improve Readmissions Through InteGrated Hospital Transitions (AIRTIGHT)

Hospital Readmission

United States
Coherus Biosciences, Inc.
Shanghai Junshi Bioscience Co., Ltd.; Medpace, Inc.

Active, not recruiting

Study to Evaluate Safety and PK of CHS-006 in Combination With Toripalimab in Patients With Advanced Solid Tumors

Hepatocellular Carcinoma | Non-Small Cell Lung Cancer | Advanced Solid Tumor

United States
Bliss Biopharmaceutical (Hangzhou) Co., Ltd

Active, not recruiting

A First-in-human Study of Multiple Doses of BB-1701 in Subjects With Locally Advanced/Metastatic HER2 Expressing Solid Tumors

Locally Advanced/Metastatic HER2 Positive Solid Tumors

China, United States
Shanghai Chest Hospital

Not yet recruiting

SHR-1701 for Consolidation Therapy After Concurrent Chemoradiotherapy in Inoperable Stage III NSCLC

NSCLC, Stage III
Atridia Pty Ltd.

Completed

A Trial of SHR-1701 in Subjects With Advanced Solid Tumors

Advanced Solid Tumor

Australia
Jiangsu HengRui Medicine Co., Ltd.

Active, not recruiting

SHR-1701 in Subjects With Metastatic or Locally Advanced Solid Tumors

Solid Tumor

China
Jiangsu HengRui Medicine Co., Ltd.

Recruiting

SHR-1701 in Metastatic or Locally Advanced Solid Tumors

Solid Tumor

China
Ceragem Clinical Inc.

Not yet recruiting

CETIC-I (CEra Traction Improves Cervical Kyphosis -I)

Kyphosis | Cervical Kyphosis | Cervical Lordosis
Cyclerion Therapeutics

Completed

A Trial of IW-1701, A Stimulator of Soluble Guanylate Cyclase (sGC), in Healthy Subjects

Healthy

United States
Jiangsu HengRui Medicine Co., Ltd.

Not yet recruiting

SHR-1701 in Combination With Famitinib in Patients With Recurrent/Metastatic Nasopharyngeal Carcinoma

Nasopharyngeal Carcinoma

China
Suzhou Suncadia Biopharmaceuticals Co., Ltd.

Not yet recruiting

Study of SHR-1701 Plus BP102 in Subjects With Selected Solid Tumors

Advanced or Metastatic Non-squamous Non-small Cell Lung Cancer
Suzhou Suncadia Biopharmaceuticals Co., Ltd.

Recruiting

Trial of SHR-1701 Plus BP102 in Subjects With Selected Solid Tumors

Advanced Solid Tumors

China
Jiangsu HengRui Medicine Co., Ltd.

Recruiting

A Trial of SHR-1701 in Combination With Famitinib in Patients With Advanced Solid Tumors

Solid Tumor

China
Icahn School of Medicine at Mount Sinai
IRRAS

Recruiting

Intraventricular Catheter System for IVH (DIVE)

Intraventricular Hemorrhage (IVH)

United States
Cyclerion Therapeutics

Completed

Trial of IW-1701 (A Stimulator of Soluble Guanylate Cyclase (sGC)) in Healthy Volunteers

Healthy

United States
Chinese PLA General Hospital

Recruiting

SHR1701 Alone or in Combination With SHR2554 in Relapsed or Refractory Classical Hodgkin Lymphoma

Relapsed or Refractory Hodgkin Lymphoma

China
Cyclerion Therapeutics

Completed

A Study of the Effect of IW-1701 (Olinciguat), a Stimulator of Soluble Guanylate Cyclase (sGC), on Patients With Sickle Cell Disease (SCD) (STRONG SCD)

Sickle Cell Disease

United States, United Kingdom, Lebanon
Cyclerion Therapeutics

Terminated

Study of IW-1701, A Stimulator of Soluble Guanylate Cyclase (sGC), in Patients With Type I or II Achalasia

Achalasia

United States
Gilead Sciences

Withdrawn

A Phase 2, Single-Arm, Open-Label Study Evaluating the Efficacy and Safety of Single Agent GS 1101 (CAL 101) as Therapy for Previously Treated Chronic Lymphocytic Leukemia

Chronic Lymphocytic Leukemia
Cyclerion Therapeutics

Completed

A Trial to Study the Absorption, Metabolism, and Excretion of [14C]-Olinciguat in Healthy Male Volunteers

Healthy Volunteers

United States
Suzhou Suncadia Biopharmaceuticals Co., Ltd.

Not yet recruiting

Phase Ib/II Study of Almonertinib Combined With SHR-1701 in the Treatment of Relapsed or Advanced Non-small Cell Lung Cancer

Relapsed or Advanced Non-small Cell Lung Cancer
Reata, a wholly owned subsidiary of Biogen

Completed

Safety and PK/PD of RTA 1701 in Healthy Adults

Healthy

Australia
Gilead Sciences

Completed

Study to Investigate Effects of CAL-101 in Subjects With Allergic Rhinitis Exposed to Allergen in an Environmental Chamber

Allergic Rhinitis

Austria
Fudan University

Recruiting

A Clinical Trial of Breast Cancer Neo-adjuvant Therapy Based on Molecular Pathway in FUSCC

Breast Cancer

China
Coherus Biosciences, Inc.

Recruiting

Study of CHS-114 in Participants With Advanced Solid Tumors

Advanced Solid Tumor | Head and Neck Squamous Cell Carcinoma

United States
Jiangsu HengRui Medicine Co., Ltd.

Unknown

SHR-1701 in Patients With Recurrent/Metastatic Scchn

Squamous Cell Carcinoma of Head and Neck

China
Eisai Inc.
Bliss Biopharmaceutical (Hangzhou) Co., Ltd

Recruiting

A Study of BB-1701 in Previously Treated Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive or HER2-low Unresectable or Metastatic Breast Cancer

Breast Cancer

United States
Gilead Sciences

Terminated

An Extension Study for Subjects Who Are Deriving Benefit With Idelalisib (GS-1101; CAL-101) Following Completion of a Prior Idelalisib Study

Lymphoma, Non-Hodgkin | Chronic Lymphocytic Leukemia

United States
Gilead Sciences

Completed

Safety and Efficacy Study of Idelalisib (GS-1101, CAL-101) in Patients With Previously Treated Low-grade Lymphoma

Follicular Lymphoma | Marginal Zone Lymphoma | Small Lymphocytic Lymphoma | Indolent Non-Hodgkin's Lymphoma

United States
Paion UK Ltd.
Premier Research Group plc

Completed

Multiple Dose Safety and Efficacy Study Evaluating CNS 7056 Versus Midazolam in Patients Undergoing Colonoscopy

Sedation

United States

Search clinical trials for: CHS-1701

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Cambodia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations